When was Barinthus Biotherapeutics founded?

Barinthus Biotherapeutics was founded in 2016 and raised its 1st funding round within a year of its incorporation.

Where is Barinthus Biotherapeutics located?

Barinthus Biotherapeutics is headquartered in Germantown, United States. It is registered at UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE,HARWELL,DIDCOT,UNITED KINGDOM,OX11 0DF.

Who is the current CEO of Barinthus Biotherapeutics?

Bill Enright of Barinthus Biotherapeutics.

Which legal entities is Barinthus Biotherapeutics associated with?

Barinthus Biotherapeutics is associated with VACCITECH (UK) LIMITED and 1 other.

How many employees does Barinthus Biotherapeutics have?

As of Sep 30, 2026, the latest employee count at Barinthus Biotherapeutics is 34.

Is Barinthus Biotherapeutics a funded company?

Barinthus Biotherapeutics is a funded company, having raised a total of $210M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 12, 2016.

When was the latest funding round of Barinthus Biotherapeutics?

Barinthus Biotherapeutics' latest funding was a $***** Post IPO round on Dec 25, 2023, with participation from 1 investor.

What is the annual revenue of Barinthus Biotherapeutics?

Annual revenue of Barinthus Biotherapeutics is between $10M and $50M as on Dec 31, 2024

Where does Barinthus Biotherapeutics rank among its competitors?

Barinthus Biotherapeutics ranks 43rd amongst 2604 active competitors, of which 883 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Barinthus Biotherapeutics?

Barinthus Biotherapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Barinthus Biotherapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of T-cell immunotherapeutics to treat multiple diseases. The company has proprietary platform technologies ChAdOx, MVA, SNAP-TI, and SNAP-CI to develop pipeline of product candidates across a diverse range of therapeutic areas including chronic infectious diseases, autoimmunity, and cancer.

Website: barinthusbio.com
Social
Email ID: *****@barinthusbio.com
Phone Number: +1 **********
Registered Address: UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE,HARWELL,DIDCOT,UNITED KINGDOM,OX11 0DF

Key Metrics

Founded Year

2016

Location

Germantown, United States

Stage

Public

Total Funding

$210M in 4 rounds

Latest Funding Round

Post IPO, Dec 25, 2023, $*****

Investors

Oxford Science Enterprises & 13 more

Ranked

43^rd among 2604 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2024

Employee Count

34 as on Sep 30, 2026

Similar Companies

Fulcrum Therapeutics & 247 more

Exit Details

Public

View Barinthus Biotherapeutics' full profile

Barinthus Biotherapeutics is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Barinthus Biotherapeutics Plc. CIN: 1828185 , United States, Active		$10M - $50M (As on Dec 31, 2024)	-	-
VACCITECH (UK) LIMITED CIN: 9973585 , United Kingdom, Active	Jan 26, 2016	-	72 (As on Dec 31, 2021)

Barinthus Biotherapeutics got listed on Apr 30, 2021.

Click here to take a look at Barinthus Biotherapeutics's IPO in detail

Barinthus Biotherapeutics has raised a total funding of $210M over 4 rounds. Its first funding round was on May 12, 2016. Its latest funding round was a Post IPO round on Dec 25, 2023 for $*****. 1 investor participated in its latest round. Barinthus Biotherapeutics has 14 institutional investors.

Here is the list of recent funding rounds of Barinthus Biotherapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 25, 2023	9300607	Post IPO	8389290	6053515	8201504	7158267
Mar 17, 2021	7556468	Series B	2195964	4505416	1688108	Future Planet Capital & 3 more
Jan 14, 2018	8787867	Series A	3926221	4259574	Sequoia Capital & 2 more	Neptune Ventures

Access funding benchmarks and valuations. Sign up today!

View details of Barinthus Biotherapeutics's funding rounds and investors

The founders of Barinthus Biotherapeutics are Sarah Gilbert and Adrian V S Hill. Bill Enright is the CEO of Barinthus Biotherapeutics.

Here are the details of Barinthus Biotherapeutics' key team members:

Sarah Gilbert: Co-Founder of Barinthus Biotherapeutics.
Adrian V S Hill: Co-Founder of Barinthus Biotherapeutics.
Bill Enright: CEO of Barinthus Biotherapeutics.
Contact Info: 1 email address

Barinthus Biotherapeutics' Board of Directors

Barinthus Biotherapeutics's board has 2 active members. Alexander Eric Hammacher and William James Enright are independent board members.

Here is the list of Barinthus Biotherapeutics' board of directors:

Name	Type	Representing	Status	Duration
Alexander Eric Hammacher	Independent board member	-	Current	6y 7m
merbamb	Independent board member	-	Current	8y 3m
mteixbv	Independent board member	-	Past	8y 7m

View details of Barinthus Biotherapeutics's Founder profiles and Board Members

Barinthus Biotherapeutics' employee count trend

Barinthus Biotherapeutics has 34 employees as of Sep 26. Here is Barinthus Biotherapeutics's employee count trend over the years:

Employee count trend for Barinthus Biotherapeutics

Uncover Barinthus Biotherapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Barinthus Biotherapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Barinthus Biotherapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
43rd	Barinthus Biotherapeutics 2016, Germantown (United States), Public	Developer of T-cell immunotherapeutics to treat multiple diseases	$210M	HTIF, Sequoia Capital & 12 others	62/100